These investments also consider our global footprint, and we are positioned very well and strategically from a regional perspective. 12 Growth Drivers 2020 Revenue ($ Millions) Long-Term Growth Rate Sustainable Solutions $ 560 8–12% Healthcare 555 8–10% Composites / 5G 212 10% Growth in Emerging Regions 672 5% Other (GDP growth) 1,784 2–3% Pro Forma Avient $ 3,783 6.5% Q 1 2 0 2 1 P E R F O R M A N C E U P D AT E $86 $123 2020PF 2021 $0.53 $0.89 2020PF 2021 Q1 2021 – ORGANIC PERFORMANCE ( T O TA L C O M PA N Y ) 14 Sales Adjusted Operating Income $991 $1,162 2020PF 2021 + 17% Adjusted EPS + 43% + 68% (in millions) (in millions) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Q1 2021 SEGMENT PERFORMANCE 15 CAI $536 $609 Sales ($ in millions) SEM Distribution $64 $89 Operating Income (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition +14% +39% $290 $363 Sales $19 $24 Operating Income +25% +26% (1) $185 $217 Sales $22 $34 Operating Income +17% +55% SPECIALTY EBITDA MARGIN EXPANSION 16 CAI (1) 2018-2020 financial information is pro forma to include a full year of Clariant Masterbatch business acquisition 15.3% 15.2% 16.2% 19.1% 2018 2019 2020 Q1 2021 14.8% 15.2% 17.6% 19.4% 2018 2019 2020 Q1 2021 (1) SEM • Continued portfolio transformation to high-growth end markets and sustainable solutions • Clariant Masterbatch synergy realization • Investments in composites and outdoor high performance applications drive growth and mix improvements CAI EBITDA MARGIN EXPANSION 17 Legacy CAI 18.9% 18.9% 21.0% 2019 2020 Q1 2021 Legacy Clariant MB 11.9% 13.8% 17.4% 2019 2020 Q1 2021 • Early synergy capture translating to the bottom line • Positive mix with growth in healthcare, consumer and packaging end-markets • World-class vitality index of 36% represents sales from products introduced in the last five years. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 78% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of June 4, 2021 87 89 87 86 83 81 76 88 85 83 82 81 80 78 78 78 76 72 71 69 50 18 A vi e n t K W R P P G R P M A V Y F U L G C P F M C H X L U N V R IF F E C L A S H F O E C E E M N B N R H U N G R A K R A S C L A L B Source: Peer data per Bloomberg market data as of June 4, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. In 2021, we expect substantial earnings growth and strong cash flow generation as we emerge from the COVID-19 pandemic.

In certain situations, however, you may wish to remain anonymous. At Avient, we wish to build such relationships because they are in the long-term interest of Avient and the customers and vendors with whom we do business. Internal Contacts—Ethics and Compliance Resources For more information on the Code or our expectations, contact the following resources directly: • Your supervisor or any Avient manager • Your human resources representative or the Human Resources department • The Corporate Ethics Officer • Any member of the Legal department • The function with the appropriate expertise (e.g., Corporate Finance, Internal Audit, Sourcing) Ethics Hotline Call or use the Ethics Hotline if: • You need advice or have a question • You wish to raise an issue or concern • You raised an issue or concern and were not satisfied • You are not sure where to go for information • You are uncomfortable using one of the other resources listed in the Code The Ethics Hotline is available globally in over 20 languages, 24 hours a day, 7 days a week.

D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. In 2021 we expect substantial earnings growth and strong cash flow generation as we emerge from the COVID-19 pandemic. Free Cash Flow Calculation Year Ended December 31, 2020 Cash provided (used) by operating activities $ 221.6 Capital expenditures (63.7) Free Cash Flow 157.9 Payment of post-acquisition date earnout liability 38.1 Taxes paid on gain on divestiture 142.0 Adjusted Free Cash Flow $ 338.0 Year Ended December 31, 2019 Free Cash Flow Calculation Total Discontinued Operations Continuing Operations Cash provided by operating activities $ 300.8 $ 74.4 $ 226.4 Capital expenditures 81.7 14.1 67.6 Free Cash Flow $ 219.1 $ 60.3 $ 158.8 6 Avient Q4 Earnings and 2021 Outlook.pdf Avient February IR Presentation.pdf Avient IR Presentation - Goldman Sachs and Morgan Stanley - Website.pdf Avient Q4 Earnings and 2021 Outlook.pdf Avient Q4 Earnings and 2021 Outlook.pdf Avient Q4 Earnings and 2021 Outlook.pdf Avient Q4 Earnings and 2021 Outlook.pdf Avient Q4 Earnings and 2021 Outlook.pdf 2.5.21 IR Deck Attachments clean

Avient Corporation (NYSE: AVNT), with 2021 revenues of $4.8 billion, provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world.

Launched in 2021, Mevopur™ Healthcare Bio-based Polymer Solutions are color and additive concentrates and ready-to-use formulations manufactured with bio-based polypropylene, polyethylene, polycarbonate, acrylonitrile butadiene styrene, or styrenic polymers.  

Introduced in 2021, the Mevopur portfolio also includes custom color and additive concentrates and ready-to-use formulations made with bio-based polyolefins, polycarbonate, acrylonitrile butadiene styrene, or styrenic polymers.

About Avient Avient Corporation (NYSE: AVNT), with 2021 revenues of $4.8 billion, provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world.

Avient expects to introduce solutions throughout 2021 as new data is generated.

About Avient Avient Corporation (NYSE: AVNT), with 2021 revenues of $4.8 billion, provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world.

CTC 17 May 2021.pdf